StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) stock

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.50+1.40 (+2.09%)

Close on Nov 17, 2026Market cap $16.71BP/E 20.5Yield –

Exelixis price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Exelixis's price to sales ratio was 7.2× on Nov 11, 2026, against 5.2× a year earlier. Over the last 5 years it ranged from 3.2× to 7.2×, with a median of 4.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20267.2×+2.1
2025Dec 31, 20255.1×+0.6
2024Dec 31, 20244.6×+0.4
2023Dec 29, 20234.2×+1.0
2022Dec 30, 20223.2×−1.5
2021Dec 31, 20214.6×−1.9
2020Dec 31, 20206.5×+0.9
2019Dec 31, 20195.6×−2.3
2018Dec 31, 20187.9×−14.0
2017Dec 29, 201721.9×−12.5
2016Dec 30, 201634.5×−2.4
2015Dec 31, 201536.9×+24.2
2014Dec 31, 201412.7×−19.7
2013Dec 31, 201332.4×+26.2
2012Dec 31, 20126.3×+1.6
2011Jul 29, 20114.7×−1.1
2010Dec 31, 20105.8×–

More Exelixis figures

See a number that looks wrong?